Viking Therapeutics Inc. (NASDAQ:VKTX)

There are currently no videos for this stock.
To request coverage of this stock, please click the green request video box on the right.
Bands Volume 200 SMA 50 SMA 20 SMA Videos Alerts Articles Events
VKTX Weekly Chart

Old Forum Content for VKTX

Make a Forum Post
Become a member to view recent forum posts. Already a member? Sign in here.
Loading...
  • MongosPawn: $VKTX Took a small bite. Perky recently. Been trending up along the 8dma. Up 10% today likely due to another analyst giving this an "overweight" rating. Now above the 50dma. Let's see if it can hold it. Plenty of resistance above.
  • woodman: @MongosPawn $VKTX - I've been watching as well, but I'm just so sick of shitty biotech, particularly this one. But as a chart trade, I suppose it has a chance.
  • curtis: @MongosPawn $VKTX (this is a break out) https://www.tradingview.com/x/7kKNq8xk/ adding to position.
  • champ: $VKTX .... is at $29 ..and they received a #Strong-upgrade this morning, by Cantor Fitzgerald, which is a very large company, they initiates with a Overweight, with as price target at $104...... ........Watch for Entry, for a Hold and Build investment position........ and on $/23....BlackRock took out a large position, 5,031,511 shares...... ....and also on 4/23, they reported a small miss on their earnings.....and they also reported that they were holding $851 million $$$$ in cash....... .....I'm holding a New position this morning and I already added this morning. ~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
  • woodman: @MongosPawn $VKTX - Funny, the Cantor analysis and particularly its $104 PT that's moving the stock is even less than most of the PTs that have been on this stock forever. Go back to one year ago, for instance, and the PTs ranged from $98 to $138. I guess it's been long enough for everyone to forget all those loft PTs and/or it's gone low enough for everyone to get their hopes up again. As you know, I was quite involved with this stock some time ago. I abandoned ship much higher up. Trade the chart, like you are doing, but don't fall in love. Love can cause a lot of pain, and is almost guaranteed in biotech, lol!
  • Bert953: @MongosPawn $VKTX looks constructive in that price broke above the upper BB and the 50dMA. on volume. there's a slight pullback into lunch time. Earnings 7/23. R1 @ $34.
  • woodman: @Henry $LLY - LLY was able to slow titrate, which should help with tolerance. But the starting dose was low. $GPCR getting an even bigger bounce off the news. It has the same molecule, but safety/tolerance of GPCR's remains an unknown. There are doubts that the tolerance of its version will be good, particularly at high doses. $VKTX down on the LLY news, but it will provide 13 week data later this year and is expected to do even better in 13 weeks than what LLY just did in 40 weeks. I have no position in any of these stocks.
  • joelsg1: $PFE Stopped it's oral anti-obesity pill, 1 less competitor good for $VKTX and $GPCR potential acquisition.
  • woodman: @joelsg1 $PFE $VKTX $GPCR - Yep. Too bad $PFE is still swallowing the $43 billion deal for $SGEN.
  • joelsg1: @woodman $PFE $VKTX $GPCR $SGEN Lost alot of market "weight" there :)
  • joelsg1: $VKTX $GPCR Both up on Roche $5.3B deal to acquire rights to Denmark's Zealand Pharma obesity therapy. Takeout hope springs eternal.
  • joelsg1: $AMGN On this dirty no-good rotten day, some green, my healthcare $AMGN, $GPCR, $VKTX and $COO into E tonight (implied move $5.50).
  • Bert953: @joelsg1 $AMGN $GPCR $VKTX $COO Just got to my desk a few min ago. even though FINVIZ shows the 4 indexes above the opening print, looking at a few watchlists, they were a sea of red. The 2 starter positions I took yesterday were stopped out. As I said yesterday, not really a surprise. Lets see what exciting revelations, along with shock and awe come over the weekend. Not planning on doing anything til next week.
  • woodman: $VKTX - As I cautioned, don't chase biotech buyout rumors, at least in the heat of the moment. They virutally always are sell the pop provided by the rumor/speculation. There was some extremely fishy options action with this on Friday. Someone made a huge killing on the rumor, apparently trading before the rumor got out. I'm not sure the SEC functions in any way to protect retail investors, so I don't expect any theiving pumpers who benefitted to be worried about prosecution.
  • woodman: $VKTX buyout rumors moving the stock. I don't have my BS meter plugged in, so I don't know where the needle is landing.
  • Dig44north: @woodman $VKTX found this: Viking Therapeutics (NASDAQ:VKTX) quickly soared 10% amid some renewed takeover speculation for the biotech firm. There's some renewed speculation Viking (NASDAQ:VKTX) may be a takeover target, according to traders, who cited a Betaville "uncooked" alert that circulated on Friday. Pfizer (PFE) is suggested to be the company looking at VKTX, people told the M&A publication. Morgan Stanley is said to be advising. Viking Therapeutics (NASDAQ:VKTX) has a market cap of $3.5 billion. Developing story ...
  • woodman: @Dig44north $VKTX - Never heard of the outfit.
  • joelsg1: @woodman $VKTX Oh how the mighty have fallen.
  • woodman: @joelsg1 $VKTX - If I had any, I'd be selling the rumor. The final dump on the large majority of my shares was in the 50s and 60s.
  • toothdriller81: $VKTX. Any news?
  • kenb: @toothdriller81 $VKTX Scotiabank analyst coverage - sector outperform with price target $102. I wish it can climb to that.
  • DavidG: @toothdriller81 $VKTX I couldn't find anything substantive. This is the first time in 3.5 months that it has been above the 21d MA. Plenty of brokerage houses have all sorts of opinions but I don't make much of those. Maybe @Woodman might be aware of something?
  • Samara: @DavidG $VKTX Scotia bank initiated coverage with a sector outperform rating w/target of $102.00
  • woodman: @DavidG $VKTX - Lots of theories, because, you know, there's always a reason for a move, right? I don't know anything specifically attributed to this move that I'd call reliable. I saw some references to VK2735 and VK0214 trial recruitments/starts/co ...
  • woodman: @woodman $VKTX $ALT $LLY $GPCR $HIMS $NVO - Just saw this. Cowen GLP-1 Market: The Pipeline Expands - Global GLP-1 sales in 2030 could reach $139B, up from our $101B forecast a little over a year ago. The market is maturing but accruing health outcomes data should broaden access and maintain momentum.
  • woodman: @woodman $VKTX $ALT $LLY $GPCR $HIMS $NVO - Interesting that VKTX has dropped to a $3.8B market cap, and ended 2024 with a decent cash position of $903 million. But it is running multiple trials now, so it will have to burn a lot.
  • joelsg1: $VKTX E tonight, they started Phase 2 of their weight loss pill, maybe they tell us something.
  • woodman: $VKTX didn't impress anyone at JPM HC yesterday. No new news. Folks in this seem to be hoping for a buyout or partnership, which topic was essentially avoided yesterday except for a word salad response by the CEO on obesity. He didn't even discuss the NASH/MASH drug. The stock is looking for support with none to be found on the chart here as it falls through the last of what may have been deemed short term support. I got out of this, and most of my bios, some time ago. They've - what's that technical term? - sucked. I still have ARDX, but that's it other than small marker positions.
  • woodman: @Bs7518 $VTKX - $VKTX - I've kind of disconnected from VKTX over the last couple months in this current catalyst desert and relentless move down in price (I currently have only a very small, essentially a marker, position). They are working out the d ...
  • Bs7518: @woodman $VTKX $VKTX BIG Thanks always love reading you view. I'm in a small position and am staying the course.
  • Bs7518: @woodman $TSLA $EOSE $RCKT $ARDX $HUMA $TGTX $AUPH What are your thoughts on $VKTX? I've held a small position in it (cardinal Sin) but still believe in the science?
  • woodman: @Henry $NVO - $VKTX up on this news, I guess. But VKTX is hitting a major supply area at $48-$56, and I don't think has any major catalysts upcoming, so I could see it stall in that zone.
  • Henry: @woodman $NVO $VKTX I thought yesterday was VKTX's day to have a study fail
  • woodman: @Henry $NVO $VKTX Everyone gets a turn at the wheel.
  • woodman: @joelsg1 $MRK - pennywise, pound foolish move of MRK, IMO, but it does demonstrate the reality that BP isn't paying big bucks for new assets, particularly in the obesity area. At least that what seems to be the case to me. One less dance partner for $VKTX, which is now under $5 billion market cap. I have just a marker position in VKTX. I sold most of my shares in the mid $60s in mid November, and the rest of them except for marker positions in the $50s. I'll keep watching. I don't think the company will take low ball offers, so it may have to go it alone for a while as it gears up for a Phase 3 subQ trial and Phase 2 oral trial. Biotech pretty much sucks across the board. Hence my move out of biotech positions.
  • joelsg1: @woodman $MRK $VKTX $112M cash for a license flyer may set the template for future deals, hurting $VKTX and my $GPCR. Like your pun "pound foolish" :)
  • woodman: @joelsg1 $MRK $VKTX $GPCR - Ha, unintended pun!
  • woodman: @joelsg1 $AMGN $LLY - I'm not surprised by the $AMGN tolerability/safety issues. That's always been the supposition. AMGN (as have some others) has not been transparent with safety concerns. The future of obesity meds isn't just weight loss %, but safety and tolerability. If you can't stay on the drug because you're always puking or feel like crap, you won't stay on and the weight loss numbers are meaningless. The yellow flags have always been there with AMGN. It should stop effing around and buy $VKTX. JMHO.
  • joelsg1: @woodman $AMGN $LLY $VKTX $AMGN mgmt stubborn, they will adjust, persevere and no way admit defeat buying $VKTX, their injectable is once a month or less frequent so don't know how persistent nausea.
  • joelsg1: @woodman $AMGN $LLY $VKTX Reading more about MariTide. The reported nausea lasted avg. 6 days and then resolved, surprising that when trial ended many participants maintained their weight loss for as long as 150 days, probably a function of this drug being an antibody different from the other GLP-1s which also blocks gut hormone GIP, unlike the others. Stay tuned.
  • woodman: @wineinquirer $VKTX - Here's my take. Wait for the end. https://youtu.be/Lj4SX13CTgU?si=kiiC6nLBKzrgvWU8

    Okay, more seriously, I don't think there are near term catalysts to make this thing move up siginificantly. Starting the next trials - Phase 2 ...
  • marklesparkle: @woodman $VKTX Thank you for the chuckle Total Consciousness
  • woodman: ...
    I mentioned recently that I had very significantly reduced my biotech holdings. $VKTX, for example, I sold out of entirely earlier this month between $65-$60. Not sure when I'll get back in, but it's a falling knife right now and there aren't any si ...
  • Geewhiz: @woodman $VKTX $HUMA $ARDX $TGTX Thank you for your assistance in understanding the impermanence of biotech. Have a great weekend.
  • joelsg1: $AMGN $VKTX $AMGN refuted that note put out yesterday by Cantor analyst (seemingly trying to and succeeding in manipulating the stocks) that their anti-obesity drug MariTide showed any bone density concerns in Phase 1. Long both.
  • joelsg1: @woodman $AMGN $VKTX $ARDX $HUMA $IOVA My amulet Magic 8 ball is illegible :)
  • woodman: @joelsg1 $AMGN $VKTX - For VKTX https://www.wikihow.com/Remove-Black-Magic-Spells Could work for $ARDX $HUMA and $IOVA as well. I very significantly lightened up on all of these, some completely out of now for the time being. HUMA I had lightened up ...
  • curtis: $VKTX adding small to existing position at 54.75
  • Simar297: @curtis $VKTX what would be short term stop loss ??
  • curtis: @Simar297 $VKTX (It is not a trade, but a long term investment). No stop
  • Simar297: @curtis $VKTX thanks Cutis
  • sbw1: $VKTX woke up all of a sudden, don't see any news
  • woodman: @sbw1 $VKTX - oversold, I'm guessing.
  • joelsg1: @woodman $VKTX Chatter that $AMGN had some bad news on its weight-loss drug down $20 fast, good for $VKTX $LLY $NVO.
  • woodman: @joelsg1 $VKTX $AMGN $LLY $NVO - yes, I just saw that. All the competetors seem to have bad news. VKTX continually shows it has the best version. It will move VKTX stock up, but I doubt for long. There are no significant price-moving catalysts on the horizon, and as we know, even good data can have a reverse effect. Moreover, the CEO has made it fairly clear he doesn't intend to commercialize but wants to get it through Phase 3 (which will take a while), so I'd think that's like telling Big Pharma "we have no leverage, so you can wait until price comes way down to buy us."
  • woodman: @joelsg1 $VKTX $AMGN $LLY $NVO - sounds like Cantor finally figured out the bad bone mineral density data on MariTide, which have been available since maybe February. One would think analysts could do a better job of actually reading shit.
  • joelsg1: @woodman $VKTX $AMGN $LLY $NVO Nobody reads carefully anymore, that was my superpower as a lawyer.
  • MongosPawn: $VKTX Added a little. Long.
  • RD: $VKTX Viking Therapeutics to Participate at Upcoming Investor Conferences Truist Healthcare Conference Details: Viking management will participate in a fireside chat and in 1-on-1 meetings Conference Date: November 7, 2024 Fireside Chat Timing: 12:30 – 1:00 p.m. Eastern on Thursday, November 7, 2024 Location: New York, NY UBS Global Healthcare Conference Details: Viking management will participate in 1-on-1 meetings Conference Dates: November 11-14, 2024 Location: Rancho Palos Verdes, CA Stifel 2024 Healthcare Conference Details: Viking management will deliver a corporate presentation and participate in 1-on-1 meetings Conference Dates: November 18-19, 2024 Presentation Timing: 8:35 – 9:05 a.m. Eastern on Tuesday, November 19, 2024, webcast available Location: New York, NY Jefferies London Healthcare Conference 2024 Details: Viking management will deliver a corporate presentation and participate in 1-on-1 meetings Conference Dates: November 19-21, 2024 Presentation Timing: 9:00 – 9:25 a.m. GMT on Thursday, November 21, 2024 Location: London, UK
  • traderbren: $VKTX - making a push to clear the 8ema and 20d overhead - could attract a bid if it does.
  • woodman: $VKTX - getting a little bounce off rising support and 50d area. That said, I don't see a significant catalyst for this in the near term. There are a couple things on near-term horizing, like the liver conference this month (relating to its MASH drug ...
  • DavidK: @woodman $VKTX this stock was discussed on fast money last night with some analyst. Bottom line he said buy it on weakness don’t sell the weakness . He mentioned Merck a few times as a possible partner or buying company
  • woodman: @DavidK $VKTX - Yes. I posted the clip here in the forum last night. A buyout doesn't enter my calculus for whether or not to own VKTX. It's fool's gold in many ways. If it comes to be, wonderful; no one would be happier than I would be. But I own it for fundamental reasons as a long term holding without regard to potential buyout. That's not to say a buyout won't ever happen. But I just can't spend time thinking about it. Of all the things out of our control and impossible to get any read on - which are most things in biotech - a buyout may be the #1 thing on that list, IMO.
  • woodman: $AZN selling off on bad obesity tolerability data and unimpressive weight loss for all those side effects. More evidence that $VKTX has the best mousetrap.
  • woodman: $VKTX - Viking CEO on ‘shocking’ market reaction to oral obesity data, preparing for Phase 3
    https://endpts.com/viking-ceo-on-shocking-market-reaction-to-oral-obesity-data-preparing-for-phase-3/
    Kyle LaHucik
    Senior Reporter
    SAN ANTONIO & ...
  • kenb: $VKTX reached a high of $91.71 early pre-market and has backed off that level to about $77 now.

    07:18 AM EST, 11/04/2024 (MT Newswires) -- Viking Therapeutics (VKTX) shares rose more than 13% in premarket trading Monday as the company reported new & ...
  • traderbren: @kenb $VKTX Oppenheimer Adjusts Viking Therapeutics Price Target to $164 From $138, Maintains Outperform Rating
  • kenb: @traderbren $VKTX yes, and based on the news I am expecting more upward adjustments from other analysts as well. 08:58 AM EST, 11/04/2024 (MT Newswires) -- Viking Therapeutics (VKTX) has an average rating of Buy and price targets ranging from $80 to $164, according to analysts polled by Capital IQ.
  • Cjauger: $VKTX acting frisky
  • woodman: @Cjauger $VKTX - The oral efficacy data are very good and the oral tolerability data are excellent - best in class as far as I can tell. The subcutaneous data seem to support monthly dosing, which is a big differentiater. I'm very pleased with the data, but obviously the price move is not what was hoped for as traders flip in and out and sell the news takes hold. Longer term, I don't think the company could have reasonably asked for better results which met/exceeded what the analysts were thinking/hoping to see. JPM and Oppenheimer out with positive reviews. How price reacts from here in the short term, I don't know. Longer term, the company is very much on a good track. https://www.prnewswire.com/news-releases/viking-therapeutics-reports-new-data-from-vk2735-obesity-program-at-obesityweek-2024-302294915.html
  • Cjauger: @woodman $VKTX Lots of profit-taking right now. Nasty red bar
  • Nepenthe: @Cjauger $VKTX Yeah, everything I sold it for in pre-market at 78.50, has now been wiped out. And so it goes...Cheers.
  • woodman: @Cjauger $VKTX - Sell the news event for traders, and shorts are emboldened by that as well. It's an over-crowded trade. Election week jitters can't help. Long term, this company continues to be on the right track, under-promising and over-delivering in terms of data. Folks need to know what they hold and why - as a trade? or as long term? - they hold it.
  • Cjauger: @Nepenthe $VKTX I had a nice profit at the open, sold all of it as it failed to rise above VWAP, and continued lower.
  • Cjauger: @woodman $VKTX staying on my watchlist
  • Cjauger: @woodman $VKTX Going back to 50 day
  • woodman: @Cjauger $VKTX - looks like it.
  • billyzeke: @Cjauger $VKTX I bought a tiny amount right here @ 67 just to have it in my account to watch.
  • DavidK: $VKTX- talk about losing some weight . This stock is trimming down fast . Glad I didn’t jump on some this am . What’s wrong with the data ?
  • woodman: @DavidK $VKTX - Nothing. Do some reading.
  • joelsg1: @woodman $VKTX Traveling today but data looks good though apparently small patient size, couldn’t take advantage of early pop. Haven’t seen anything about $GPCR abstract but not at computer.
  • woodman: @joelsg1 $VKTX $GPCR - number is small per mg because they had so many different cohorts/strata testing various mg's. Overall, not such a small number. No oral candidate out there has as good tolerability as VKTX has. If a patient can't tolerate the side effects, he or she won't stay on the drug. That's a differentiation that doctors will covet.
  • Geewhiz: @DavidK $VKTX Viking Therapeutics Inc. cheered analysts Monday after the biotech posted data on its oral weight-loss drug showing better-than-expected results from a Phase 1 trial.

    The news sent the stock sharply higher in premarket trade, before it ...
  • DavidK: @Geewhiz $VKTX thanks . I did read the release earlier and was curious why the negative reaction. My take more sellers than buyers is usually how it works but why I don’t know .
  • Simar297: Is $vktx is addable at 50 day which is 65ish ???
  • mikethompson: @Simar297 $vktx I would wait for the bounce.
  • mopick: @Simar297 $vktx, am going to buy a small amount here at the 50 ema. Down 10% seems overdone. Oppenheimer goes to an astonishing $164 target.
  • MongosPawn: @Simar297 $vktx I added small. Long.
  • crank: @MongosPawn $vktx I sold downside strike puts.
  • woodman: $VKTX - article from Endpoints News.

    Viking's oral weight loss drug appears to have strong effect in Phase 1 trial

    SAN ANTONIO — Viking Therapeutics’ highly anticipated readout of its oral anti-obesity pill showed a placebo-adjusted wei ...
  • woodman: $VKTX - Fast Money segment with an analyst covering VKTX. At 2:47 of the video, when the analyst is asked by Carter Worth if he thinks it's a buy here, the analyst says yes. https://youtu.be/SDZKbz2o6E0?si=rOooUXbj9mgtnugc
  • Nepenthe: $VKTX @Dan, et al. I still hold some as I missed Dan's stop alert, and had sold some in the 80's, so low CB. He mentioned looking for a phase 3 re-entry. What point might that be according to him and others? Would it be at the 8ema, or a break above the high of 81.72? For some reason, perhaps a bourbon addled brain, I never seem to catch this phase. Cheers.
  • woodman: @marklesparkle $HUMA - I remain hopeful of its first approval for ATEV, and I lean toward it being approved, but after the odd delay I reduced my position as a precaution. I'm okay with missing out on a huge profit if approved and the stock flies hig ...
  • woodman: $VKTX - there seems to be some confidence going into Sunday's data presentation.
  • joelsg1: @woodman $VKTX Little noticed, but $GPCR also presenting Sunday and Monday and stock above all converging avgs.
  • Aibistin-1: @woodman $VKTX It's forming a cup with handle type pattern on the weekly chart.
  • woodman: @joelsg1 $VKTX $GPCR - Interesting.
  • traderbren: $VKTX - holding up in this tape.
  • scottrades: @traderbren $VKTX Could be a lot worse considering some of the charts I'm seeing out there today.
  • Ben: @woodman $VKTX went against the tide today. One of two GREENS on my screen. With the Bigs $meta, etc saying they are spending big on AI, why is $NVDA and friends taking a hit? High demand seems like a high quality problem. What'd Imiss here?
Visit the Trading Forum to join in the discussion.
Stock Price $24.81
Change -3.61%
Volume 4,041,470

Viking Therapeutics Inc is a clinical-stage biopharmaceutical company. The Company develops therapies for metabolic and endocrine disorders. It includes portfolio of five drug candidates in clinical trials or preclinical studies.

Request Video of VKTX
Already a member? Sign in here.
Past Month

Leading Peers

Past Month

Lagging Peers

Dan Fitzpatrick

Stock Market Mentor gives you EVERYTHING you need to succeed in the market; all in one place. How easy is that? Dan Fitzpatrick and his elite community of traders share trading ideas, strategies and much more. Dan Fitzpatrick--a world class Technical Analyst, trading coach and regular CNBC contributor--gives you access to all of this with a 30 day trial membership for just $7.77. Get started TODAY and start trading better TOMORROW with the following premium content:

  • Nightly video Strategy Sessions with a game plan for tomorrow
  • Got a stock you want Dan to look at? Just ask.
  • Patent pending video alerts instantly delivered to you when one of Dan’s trading signals is triggered. This is not your typical price alert. This is a short video explaining the action you need to take to make money. No more “Woulda, coulda, shoulda”
  • Access to over 90,400 stock analysis videos
  • Access an ever expanding library (90,400) of educational videos that will save you time and make you money

Join a team of friends and traders that have one thing in common; a burning desire to succeed.

Become a Member Today!

Gain immediate access to all our exclusive articles, features, how-to's, discussion group and much more...

Satisfaction Guaranteed!

Your Stock Market Mentor membership comes with a 30 day, no questions asked, 100% money back guarantee!